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e.2012.03Abstract Background: Cell-free DNA (CFDNA) is extracellular nucleic acids found in cell-free
plasma/serum of humans. This study aims to quantitatively measure CFDNA concentration and
integrity in patients with malignant and non-malignant diseases and in healthy controls to investi-
gate their value as a screening test for cancer, and then to correlate them with the clinicopatholog-
ical parameters of cancer patients.
Aim: This study included 145 subjects divided into three groups; group I: 83 patients with different
types of cancer, group II: 30 patients with benign diseases and group III: 30 normal healthy volun-
teers as control. One plasma sample was collected from each subject. CFDNA was extracted from
plasma and its concentration was measured using Quant-iT PicoGreen dsDNA Assay Kit, then
CFDNA integrity was detected by conventional PCR for 100, 200, 400 and 800 bp.
Results: Results revealed that there was a highly signiﬁcant difference in the mean level of CFDNA
between the cancer group and each of the benign and control groups. AUC of ROC curve for cancer
group versus normal and benign groupswere 0.968 and 0.928,which indicated the efﬁciency ofCFDNA
as amarker for cancer. As for CFDNA integrity, normal and benign subjects showed only two bands at
100 and 200 bp, while all cancer patients demonstrated the 100, 200 and 400 bp bands and 78% of can-
cer patients had the 800 bp whose presence was statistically correlated with vascular invasion.ri.edu.eg (E. R. Zaher).
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188 E.R. Zaher et al.Conclusion: Subjects with CFDNA 6100 ng/ll would be cancer-free; subjects with CFDNA value
P600 ng/ll could be diagnosed as cancer patients, while those with CFDNA between 100 and
600 ng/ll will need DNA integrity to identify non-cancer from cancer patients. Thus plasma CFDNA
in combination with DNA integrity could be used as a screening test for cancer detection.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Cancer is a major public health problem worldwide. In the
United States, it is the second most common cause of death
and it accounted for 1 of every 4 deaths in 2008.1 In 2007,
11 million new cancer cases and 7.4 million cancer deaths were
reported worldwide; leaving nearly 25 million persons living
with cancer. More than 70% of all cancer deaths occurred in
low- and middle-income countries. Deaths from cancer world-
wide are projected to continue rising, with an estimated 12 mil-
lion deaths in 2030.2,3
In Egypt, in the years 1999–2001 the age standardized inci-
dence rates of breast cancer was 49.6/100000 females.4 In the
Egyptian mortality statistics in 2001, breast cancer was the
fourth most common cause of death, accounting for 9.3% of
all cancer deaths and 21.0% of women cancer deaths.5
A sensitive assay that can accurately diagnose the onset of
cancer using non-invasively-collected clinical specimens is ideal
for early detection. The earlier and more accurate the diagnos-
tic biomarker can predict disease onset, the more valuable it
becomes.6 Since cancer symptoms usually appear when tumors
are sufﬁciently large, so, for the detection of cancer to be early,
it has to uncover tumors in asymptomatic individuals. Early
detection reduces the suffering and cost to society associated
with the disease. The better clinical outcomes associated with
early detection highlight the need for and the potential beneﬁt
of early detection of cancer.7,8
Cell-free DNA (CFDNA) is made up of extracellular nucleic
acids found in cell-free plasma/serum of humans. There are sev-
eral terms in use like circulating nucleic acids, extracellular nu-
cleic acids or cell-free nucleic acids.9 Circulating extracellular
DNA can be found in healthy persons, persons with non-malig-
nant diseases, as well as persons with various malignancies. In
addition, trauma and therapeutic procedures may also lead to
the release of free DNA into the circulation. It is likely that a
signiﬁcant proportion is bound to protein molecules, possibly
as nucleosomes.10,11 Theoretically, circulating DNA is mostly
released from degrading cells after cleavage by endonucleases
that cut the chromatin into the basic nucleosomes, which con-
serves them from proteolytic digestion in blood.12
In a healthy person, it is believed that CFDNA enters circu-
lation via apoptosis of lymphocytes and other nucleated cells.13
Apoptosis is an active and energy-requiring process of cell death
that plays a critical role in physiological functions, and that has
a distinctive DNA ‘‘ladder’’ pattern that showed speciﬁc
banding at 200 bp. The banding pattern was apparently due to
endonuclease-mediated double-strand cleavage between nucle-
osomes.14–16 While in cancer patients, CFDNA most likely re-
sults from tumor necrosis, but other suggested mechanisms
include lysis of circulating cancer cells or of micro-metastases,
or due to active release.17 Necrosis is a passive process that usu-ally affects large cell clusters and results from insufﬁcient vascu-
larization and persistent ischemia. Tumor necrosis generates a
spectrum of DNA fragments with different strand lengths,
mostly large DNA fragments, because of random and incom-
plete digestion of genomic DNA by a variety of DNAases.18
The current work aims to quantitatively evaluate the levels
of plasma DNA and to determine its integrity in patients with
malignant and non-malignant diseases and in healthy controls
to investigate their potential role as a screening, non-invasive
tool for cancer detection, and determine their correlation to
clinicopathological characteristics of speciﬁc tumors. CFDNA
concentration and integrity were also evaluated for each cancer
type included in the study to verify that it stands for each of
them separately.2. Subjects and methods
2.1. Subjects
This prospective cohort study included 145 subjects divided
into three groups:
Group I: included 85 patients newly diagnosed with cancer
of different types (24 Breast, 14 Lung, 14 Colon, 13 stom-
ach and 10 HCC cancers and 10 Lymphoma).
Group II: included 30 patients with various benign diseases
(excluding autoimmune diseases) of matched age and sex to
group I (12 benign breast lump, 3 colitis, 2 benign colonic
polyps, 5 duodenal ulcers, 3 cirrhosis and 5 inguinal hernia).
Group III: included 30 normal healthy volunteers of
matched age and sex to group I, as controls.
Patients were randomly recruited from those admitted to
Experimental and Clinical Surgery Department and Cancer
Research and Treatment Department, Medical Research Insti-
tute, Alexandria University. Samples were collected during the
period from January 2007 to December 2008. All patients pro-
vided an informed written consent and the study was approved
by the Local Research Ethics Committee of the Medical Re-
search Institute, Alexandria University.
Patients were subjected to standard clinical procedure
according to the type of disease; these include thorough clinical
examination, preoperative evaluation by FNAC, endoscopy or
excision biopsy, full medical history taking and full routine
laboratory and radiological investigations.
Breast, colonic and gastric carcinoma patients underwent
surgery. Modiﬁed Radical Mastectomy was done to all 24
breast cancer patients. Right hemicolectomy was done to four
patients, left hemicolectomy was done to three patients and
anterior resection was done to seven patients with colonic
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and total gastrectomy to ﬁve patients with gastric carcinoma.
Lymph nodes excisional biopsies was done for lymphoma pa-
tients. All patients received their standard adjuvant chemo-
therapy according to the type of cancer they had.
One random blood sample was collected in EDTA-contain-
ing tubes, from patients before surgery or treatment and from
controls. Blood was centrifuged at 6000 rpm for 10 min at
4 C. Plasma samples were kept frozen at 80 C until the time
of assay to detect Total Cell Free DNA, DNA integrity and
DNA integrity index.19.
2.2. DNA extraction
DNA extraction from serum was performed using Nucleo-
Spin Plasma XS kit (Macherey–Nagel GmbH & Co. KG,
Germany) according to the manufacturer’s instructions.
Brieﬂy, 20 ll proteinase K was added to 240 ll plasma, incu-
bated at 37 C for 5 min. To the mixture, 360 ll of Binding
Buffer was added, mixed for 60 s. and then loaded into the col-
umn. The column was centrifuged at 6000 rpm for 30 s then at
12,000 rpm for 5 s. The column was washed twice. 30 ll of Elu-
tion Buffer was added to the column and left for 10 min. DNA
was collected by centrifugation at 12,000 rpm for 30 s. The elu-
tion fraction was incubated with open lid for 8 min at 90 C.
2.3. DNA quantiﬁcation
CFDNA concentrations of extracted samples were measured
using Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen
Detection Technologies) according to the manufacture’s
instructions. Calf thymus DNA (100 mg/ml) was used as a
standard to prepare serial dilutions (0–1000 ng/ml) to plot a
standard curve. Fluorescence intensity was measured in a spec-
troﬂuorometer at emission wavelength of 520 nm and excita-
tion wavelength of 480 nm.
2.4. PCR ampliﬁcation
The integrity of CFDNA was examined by PCR. Three frag-
ments were ampliﬁed of 200, 400 and 800 bp for p-53 gene, in
addition to a 100 bp b-actin fragment as a house keeping gene.
PCR was carried out using Go TaqGreen Master Mix (Pro-
mega Corporation-Madison, WI, USA). Each PCR reaction
mixture consisted of 10 ll PCR master mix; 1 ll of each ampli-
ﬁcation primer 4 lM (4 pmol/ll) and 250 ng of extracted DNA
and the volume was brought to 20 ll by adding deionized
water. Thermal cycling started by a ﬁrst denaturation step of
4 min at 95 C, followed by 45 cycles of 95 C for 30 s, 58 C
for 60 s and 72 C for 60 s and a ﬁnal extension at 72 C for
10 min. Two separate ampliﬁcations were used one for b-actin
with the primer sequences as follows: F-GCACCACACCTTC-
TACAATGA and R-GTCATCTTCTCGCGGTTGGC, the
second ampliﬁcation for p-53 gene was carried out using one
forward primer whose sequence was F-CACCTCCACCACCT
CCTCAA and three reverse primers R1-GTATCAGCATCT
GGAAGAA at 200 bp, R2-CATCATCATCTGAATCATCT
at 400 bp and R3- TCACCTGACTGTGCTCCTCC at
800 bp. PCR products were then separated by gel electrophore-
sis, stained by ethedium bromide and visualized by UV. Band
intensities were measured by Scione Image software, which
analyzes relative band intensities in Arbitrary Units (AUs)depending on the color and width of the band, and were used
to calculate the Integrity Index.
2.5. Tumor marker evaluation
Standard serum tumor markers for each type of cancer were
also evaluated. For breast cancer patients, CA 15.3 was mea-
sured using a commercial immunoradiometric assay (IRMA)
kit (DIAsource ImmunoAssays S.A. – Belgium). For lung can-
cer patients, CYFRA 21–1 was measured using a commercial
IRMA kit (SIS Bio International, Schering S.A., France).
For colon and gastric cancer patients CA 19.9 was measured
using a commercial IRMA kit (DIAsource ImmunoAssays
S.A. – Belgium). For HCC patients AFP was measured using
a commercial IRMA kit (DIAsource ImmunoAssays S.A. –
Belgium). All tests were carried out according to the manufac-
turers’ instructions and using the materials supplied in the kit.2.6. Statistical analysis
Statistical analysis was performed using the SPSS (Statistical
Package for the Social Sciences) software package, version
19.0 (SPSS Inc., Chicago, IL, USA).
Comparisons of means were made by the Mann–Whitney U
test for non-normal distributions. A p value of less than 0.05
was accepted as evidence of statistical signiﬁcance. Qualitative
variables were compared using the v2 test and Fisher’s exact
test. Two-tailed p values of less than 0.05 were considered evi-
dence of statistical signiﬁcance. The relationships between the
amount of DNA in the plasma and clinicopathological param-
eters were determined by Pearson correlation analysis.
A receiver operating characteristic curve (ROC) was devel-
oped to evaluate the diagnostic performance of plasma DNA
concentrations. Each unique DNA value was used as a cut-
point to calculate sensitivity and speciﬁcity values deﬁning
the curve and the area under the curve (AUC). A p value less
than 0.05 (two tailed) was considered signiﬁcant. SEs were esti-
mated separately to provide a 95% CI for the area.3. Results
The mean age of all subjects included in this study was repre-
sented as mean ± standard deviation (M± SD), the M± SE
of age in 83 patients with different types of cancer were
53.9 ± 14.6 years ranging from 32 to 75 years. While, the
mean ± SD of age in 30 benign and 30 control groups were
48.7 ± 19.7, 49.8 ± 25.7 years, respectively. The range of age
in benign and control groups was 37–60 and 38–63 years,
respectively. There was no statistically signiﬁcant difference in
the mean age between the three groups. The cancer patients
group was comprised of 54 (63.5%) females and 31 (36.5) males
with a male:female ratio of 1:2. The same male:female ratio was
maintained in the benign (20 females and 10 males) and control
groups (19 females and 11 males).3.1. Plasma CFDNA levels in studied groups and subgroups
Table 1 represents the level of plasma CFDNA (ng/ll) in can-
cer, benign and control groups. The M± SE for cancer group
was 765.1 ± 84.8 ng/ll ranging from 105 to 4891 ng/ll and for
Table 1 Levels of plasma DNA (ng/ll) in cancer, benign, and control groups and in cancer subgroups.
Groups M± SE Range p1 p2
Cancer group (n= 85) 765.1 ± 84.8*,x 105–4891 0.000 0.000
U= 54 U= 75
Breast (n= 24) 902.0 ± 226.2*,x 105–4891 0.000 0.001
U= 26 U= 26
Lung (n= 14) 744.3 ± 157.1*,x 351–2000 0.003 0.014
U= 10 U= 10
Colon (n= 14) 517.5 ± 120.6*,x 229–1550 0.008 0.016
U= 16 U= 16
Stomach (n= 13) 657.3 ± 83.6*,x 232–1111 0.003 0.013
U= 7 U= 7
HCC (n= 10) 471.3 ± 106.4*,x 142–968
Lymphoma (n= 10) 1366.1 ± 333.4*,x 171–2660
Benign (n= 30) 141.0 ± 40.2 38–597 0.237
U = 80
Control (n= 30) 75.8 ± 20.8 0–300
p1 = signiﬁcance when compared to control group by Mann–Whitney U test.
p2 = signiﬁcance when compared to benign group by Mann–Whitney U test.
*,x The mean difference is signiﬁcant at p< 0.05 when compared to the control and benign groups respectively, by Mann–Whitney U test.
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from 38 to 597 ng/ll and 75.8 ± 20.8 ng/ll ranging from 0
to 300 ng/ll, respectively.
There was a statistically signiﬁcant difference in the mean
level of plasma DNA between cancer group and each of the be-
nign and control groups (p= 0.000 and 0.000, respectively),
but there was no statistically signiﬁcant difference between be-
nign and control groups (p= 0.237).
The cancer group was divided into six subgroups according
to the tumor site; these subgroups were stomach, lung, breast,
HCC, colon and lymphoma subgroups. The M± SE for these
subgroups were: 657.3 ± 83.6, 744.3 ± 157.1, 902.3 ± 226.2,
471.3 ± 106.4, 517.5 ± 120.6 and 1366.1 ± 333.4 ng/ll, res-
pectively. There was a statistically signiﬁcant difference in
the mean level of plasma DNA between all cancer subgroups;
breast, lung, colon and stomach cancer subgroups and each ofFigure 1 ROC curve for discrimination between (a) cathe control groups (p= 0.000, 0.003, 0.008 and 0.003, respec-
tively), and the benign group (p= 0.001, 0.014, 0.016 and
0.013, respectively).
3.2. ROC curve of CFDNA
Fig. 1a represents the ROC curve of plasma DNA concentra-
tions for discrimination between cancer and control groups.
There was a statistically asymptotic signiﬁcance, p= 0.000,
with an area under the curve (AUC) of 0.962, indicating the
validity of CFDNA to discriminate cancer from control
subjects.
Fig. 1b, representing the ROC curve of plasma DNA con-
centrations for discrimination between cancer and benign
groups, showed statistically asymptotic signiﬁcance, p=
0.000, and AUC was 0.927, indicating the validity of CFDNAncer and control, and (b) cancer and benign groups.
Figure 2 ROC curve for discrimination between various cancer subgroups and control (solid line) and benign (dotted line) groups.
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While Fig. 2 represents the ROC curves of all cancer subgroups
versus benign and control groups. All cancer subgroups
showed high asymptomatic signiﬁcance from both benign and
control groups. AUC of ROC curves for the cancer subgroups
against normal and benign groups were as follow; breast
‘‘0.962, 0.923’’, lung ‘‘1.0, 0.949’’, colon ‘‘0.971, 0.918’’, stom-
ach ‘‘0.985, 0.962’’, HCC ‘‘0.920, 0.871’’, and lymphoma
‘‘0.950, 0.929’’.
Table 2 represents ROC curve values for CFDNA versus
control and benign groups, Cutoff values of plasma DNA with
their sensitivity, speciﬁcity, Positive Predictive Value (PPV),
and Negative Predictive Value (NPV). We selected two cutoffs,
the ﬁrst at 100 ng/ll; with 100% sensitivity and 75% speciﬁc-
ity; was obtained from ROC curve of cancer group versus con-
trol group that has 100% NPV, to ensure that all subjects with
lower CFDNA are true negative for cancer. The other cutoff at
600 ng/ll; with 100% speciﬁcity and 53.4% sensitivity; was ob-
tained from ROC curve of cancer group versus benign group,
that has 100% PPV, to ensure that all subjects with higher
CFDNA are true positive for cancer.Table 2 ROC curve values for CFDNA versus control and
benign groups, showing area under each curve different,
signiﬁcance, cutoff values of plasma dna with their sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value.
Cancer versus
control
Cancer versus
benign
Area under the curve (%) 96.2 92.7
p 0.000 0.000
Standard error 0.015 0.030
95% Conﬁdence interval 0.932–0.992 0.867–0.987
Cutoﬀ values 100 600
Sensitivity (%) 100 53.4
Speciﬁcity (%) 75 100
Positive predictive value % 94 100
Negative predictive value % 100 233.3. Assessment of CFDNA integrity by PCR
CFDNA integrity was assessed by PCR ampliﬁcation of four
fragments of 100, 200, 400 and 800 bp. The ﬁrst two bands
would measure CFDNA resulting from apoptosis while the
latter two, would measure CFDNA resulting from tumor
necrosis.
Fig. 3 represents the gel electrophoresis of PCR products,
showing a negative control sample (lane 2), 100 bp b-actin
fragment (lane 1), one sample of a control subject showing
one 200 bp fragment (lane 3) and two cancer samples showing
200, 400 and 800 bp fragments (lanes 4 and 5). While Fig. 4
represents two cancer cases, lanes 1 and 2 show the 100 bp
fragment and lanes 4 and 5 show the 200, 400 and 800 bp
fragments.
Both the 100 and 200 bp fragments were present in all sub-
jects of the study, cancer, benign and controls. While the
400 bp band was present in all cancer cases but not in any of
the benign or control subjects. The 800 bp band was present
in most, but not all, cancer cases, as represented in Fig. 5a.
While the 800 bp fragment was present in only half of breast
cancer cases and 64.3% of lung cancers, it was found to be
present in 100% of HCCs, colon cancers and lymphomas;
Fig. 5b.
3.4. CFDNA integrity and integrity index
The DNA integrity index is deﬁned as the ratio of longer frag-
ments to shorter fragments. The intensity of the 400 bp frag-
ment was used to calculate the integrity index as it was
present in all cancer cases, unlike the 800 bp fragment that
was absent from 21.2% of the cases. Band intensities of 100,
200 and 400 bp fragments were assessed in Arbitrary Units
(AUs). Table 3 represents the M± SE band intensity of
CFDNA fragments in AU and the M± SE of CFDNA integ-
rity index (400/100) in cancer subgroups, benign and control
groups.
Cancer group in whole and all cancer subgroups had statis-
tically signiﬁcantly higher 100 and 200 bp band intensities than
those of the benign and control groups, while no statistically
Figure 3 Electrophoresis for PCR products of two control subjects (lanes 1–3), two cancer patients (lanes 4 and 5) and negative control
(lane 2).
Figure 4 Electrophoresis for PCR products of two cancer patients.
Figure 5 (a) Percent of cases with 100, 200, 400 and 800 bp in cancer, benign and control groups; (b) percent of cases with 800 bp in all
cancer subgroups.
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band intensities of the benign and control groups.The M± SE of CFDNA integrity index for cancer group
was 1.3 ± 0.13, while no bands appeared at 400 bp for both
Table 3 M± SE of CFDNA band intensity in AU at 100, 200 and 400 bp and CFDNA integrity index (400/100) in different
subgroups of cancer, benign and control groups.
Groups Band intensity in AU (M± SE) Integrity index
100 bp 200 bp 400 bp
Cancer (n= 85) 83.0 ± 4.2a p1 = 0.000 80.9 ± 2.4
a p1 = 0.000 85.2 ± 3.8 1.3 ± 0.13
p2 = 0.000 p2 = 0.000
Breast (24) 94.4 ± 6.3a p1 = 0.000 72.2 ± 5.4
a p1 = 0.000 64.7 ± 8.2 0.66 ± 0.096
p2 = 0.000 p2 = 0.000
Lung (14) 63.4 ± 8.3a p1 = 0.000 77.6 ± 7.5
a p1 = 0.000 76.4 ± 9.5 1.42 ± 0.21
p2 = 0.001 p2 = 0.000
Colon (14) 65.2 ± 12.8a p1 = 0.000 92.4 ± 5.9
a p1 = 0.000 91.3 ± 7.0 1.97 ± 0.35
p2 = 0.002 p2 = 0.000
Stomach (13) 86.4 ± 12.6a p1 = 0.000 93.6 ± 2.3
a p1 = 0.000 92.2 ± 9.2 1.44 ± 0.39
p2 = 0.000 p2 = 0.000
HCC (10) 64.0 ± 15.1a 77.8 ± 2.8a 111.8 ± 3.2 2.14 ± 0.55
Lymphoma (10) 104.0 ± 3.6a 74.2 ± 3.7a 97.9 ± 8.2 0.93 ± 0.065
Benign (n= 30) 27.8 ± 5.9 p1 = 0.678 27.9 ± 5.9 p1 = 0.334 – –
Control (n= 30) 24.0 ± 4.3 21.8 ± 4.8 – –
p1 = signiﬁcance when compared to control group.
p2 = signiﬁcance when compared to benign group.
a The mean difference is signiﬁcant at p< 0.05 when compared to the control and benign groups, respectively.
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calculated for these two groups. The M± SE of CFDNA
integrity index for breast, lung, colon, stomach, HCC, and
lymphoma subgroups were 0.66 ± 0.096, 1.42 ± 0.21,
1.97 ± 0.35, 1.44 ± 0.39, 2.14 ± 0.55 and 0.93 ± 0.065; res-
pectively.
3.5. Correlation with the clinicopathological parameters
Clinicopathological parameters of breast, colon and gastric
carcinoma groups combined were correlated with CFDNA
concentration and integrity and with the 800 bp band intensity.
There was no correlation between any of CFDNA concentra-
tion, integrity and integrity index with clinicopathological
parameters; including pathological stage, histological grade,
tumor size, lymph node metastases and vascular invasion; ex-
cept intensity at 800 pb band which showed a strong positive
correlation with vascular invasion, r= 0.940, p= 0.005,
Table 4.
3.6. Tumor markers and CFDNA
Conventional tumor markers related to each cancer type were
evaluated and compared in cancer to both benign and controlTable 4 Correlation between plasma DNA levels and clinicopathol
Parameters Correlation with CFDNA
concentration
Co
in
r p r
Pathological stage 0.157 0.216 
Histological grade 0.227 0.067 0.
Tumor size 0.192 0.229 0.
Lymph node
metastases
0.320 0.128 
Vascular invasion 0.252 0.384 0.
P is signiﬁcant at <0.05.subjects as one group, results are presented in Table 5. ROC
curves of each cancer type revealed that they were not all suit-
able for the diagnosis of each respective type of cancer, and
that CFDNA is by far better than any of them. None of these
markers showed any signiﬁcant relation with any of the clini-
copathological parameters of patients of its respective cancer
type. Also, none of them showed statistically signiﬁcant rela-
tion with CFDNA, except Cyfra 21.1 in lung cancer patients,
which was signiﬁcantly correlated with CFDNA (p= 0.047,
95% CI: 1.02, 4.06). Absence of other signiﬁcant correlations
is most probably because of the small sample size of each indi-
vidual type of cancer.4. Discussion
Cancer is one of the leading causes of death and often requires
tumor biopsies obtained by invasive methods, and the current
screening methods fail to detect many cancers at preliminary
stages, leading to cancers being presented at later stages when
clinical symptoms start showing.20,21 Therefore, there is a need
for a screening tool to detect cancer in early stages. A screening
test should be safe, cheap, highly speciﬁc and sensitive, with a
high predictive value that can easily and quickly be used in aogical parameters.
rrelation with CFDNA
tegrity index
Correlation with intensity of
800 bp band
p r p
0.335 0.113 0.430 0.249
126 0.080 0.292 0.082
276 0.314 0.157 0.163
0.239 0.207 0.316 0.167
351 0.294 0.940 0.005
Table 5 Conventional tumor markers routinely used in cancer diagnosis in cancer patients and control group, cutoff, sensitivity,
speciﬁcity and AUC.
Tumor marker Control Cancer Cutoﬀ Sensitivity (%) Speciﬁcity (%) AUC
Mean Range Mean Range
CA 15.3 (U/ml) 24 breast cancer 8.8 0–32.5 14.5 0–200 28 62.0 70.0 0.61
AFP (ng/ml) 10 HCC 7.5 1.5–113 116 3–3300 19.8 68.2 75.4 0.70
CA 19.9 (U/ml) 27 GIT cancer 8.9 1.7–44.5 19 1–540 37 67.1 74.7 0.63
Cyfra 21.1 (ng/ml) 14 lung cancer 2.3 0.5–11 15 0.6–126 4 65.4 69.7 0.71
194 E.R. Zaher et al.large population to detect the disease with a proven
beneﬁt.20,21
The most promising as cancer screening marker is circulat-
ing cell free DNA (CFDNA).22 Previous studies suggested that
elevated plasma DNA levels may predict neoplastic disease
through two aspects. Firstly, the amount of CFDNA in plas-
ma or serum of cancer patients is more than that in healthy
individuals. Secondly, alterations that can be detected in pri-
mary tumors can also be detected in CFDNA of a cancer pa-
tient.23,24 Different hypotheses explained the origin of
CFDNA. It is supposed to be driven from necrotic or apopto-
tic cells,17,25,26 but some authors reported the possibility of an
active release from cells.17,27 The presence of DNA circulating
freely in the blood stream of healthy subjects can be related to
apoptosis. In patients with neoplastic diseases, cancer cells
may detach from the tumor mass and undergo necrosis. Or
alternatively they may actively release nucleic acids in the
blood stream.27 But the actual origin of this CFDNA remains
enigmatic. Finally, it may be the result, in variable propor-
tions, of the sum of many different mechanisms.17,28
The goal of this study is to quantify the level of plasma
DNA and to determine DNA integrity in patients with cancer
and benign diseases and in healthy controls to investigate their
value as a screening test for cancer.
In the current study, the mean level of CFDNA in cancer
group was about 10-fold that of control group and about 5-
fold that of benign group. This may be due to the release of a
substantial amount of genomic DNA into the systemic circu-
lation from tumor cells either by necrosis or active re-
lease.17,24 This is supported by the fact that genetic
alterations of tumors were detected in the CFDNA.29 An-
other suggested hypothesis is possible suppression of DNase
activity in the sera of cancer patients as an E. coli DNase
has almost no activity in plasma from cancer patients, while
in the plasma of healthy controls the same DNase seems to
work as good not as well as in a culture medium.30 However,
there was no statistically signiﬁcant difference in the mean le-
vel of CFDNA between benign and control subjects. This
perhaps could be attributed to the exclusion of patients with
diseases that are suspected to increase CFDNA concentra-
tions as autoimmune diseases.31
In this study, cancer patients were divided into six sub-
groups according to the tumor site; these are; stomach, lung,
breast, HCC and colon cancers and lymphoma. We found that
the mean level of CFDNA in all subgroups were statistically
signiﬁcantly different from the control group. Moreover, the
mean levels of CFDNA in all cancer subgroups were higher
than the mean of the benign group. Therefore, total CFDNA
concentration could be used as screening markers in stomach,
lung, colon and breast cancer patients.Previous studies were consistent with our ﬁnding of in-
creased CFDNA level in various cancer patients than those
of control and benign subjects, and most of them conﬁrmed
the high accuracy of CFDNA levels in discriminating cancer
patients from normal subjects whatever the method used to
handle the blood samples, purify and quantify plasma DNA,
but they differed in the ﬁnal concentrations.32–36 But the study
design including selection of patient and control groups and
the way clinical blood samples were handled before reaching
the laboratory had a signiﬁcant impact on CFDNA yields,
as well as, the methods used to extract and quantify CFDNA.
All these factors make for considerable variations between
studies and difﬁculty to compare the values reported by differ-
ent research groups.
To test the accuracy, sensitivity and speciﬁcity of using
CFDNA as a screening tool, we used ROC curve of cancer pa-
tients against both benign and control groups and found that
the AUC of ROC curves were 0.962 and 0.927 and the asymp-
totic signiﬁcance was 0.000 and 0.000 for both curves respec-
tively. This indicated that CFDNA represented a highly
sensitive and speciﬁc marker to discriminate cancer patients
from control and benign individuals. When compared to con-
ventional tumor markers used in various types of cancer diag-
nosis (CA 15.3 for breast cancer, AFP for HCC, CA 19.9 for
colon and gastric carcinoma and Cyfra 21.1 for lung cancer),
CFDNA was by far, much better than any of them whether in
all cancer population or in their respective cancer types. In addi-
tion, using a single test for all cancer types is much easier and
more applicable than as many tests as cancer types themselves.
The cutoff point from the ROC curve of cancer versus con-
trol groups was 100 ng/ll, with 75% speciﬁcity and 100% sen-
sitivity, a cutoff at which no false positives occurred and
patients with CFDNA concentration below this value are not
cancer patients. Another cutoff value was selected from ROC
curve of cancer against benign groups of 600 ng/ll, which gave
a corresponding 100% speciﬁcity and 53.4% sensitivity, at this
cutoff point no false negative results were obtained. Thus, pa-
tient with CFDNA P600 ng/ll could be directly diagnosed
as a cancer patient. However, patients that had CFDNA con-
centrations, between 100 and 600 ng/ll, could not be conﬁrmed
as cancer patients, because of the overlap with benign subjects.
To resolve this discrepancy, CFDNA integrity and CFDNA
integrity index may be the answer.
DNA size distribution may be used to determine the origin
of DNA whether from apoptotic or necrotic cells. Tumor
necrosis, a frequent event in neoplasms, generates a spectrum
of DNA fragments with different strand lengths because of
random and incomplete digestion of genomic DNA by a vari-
ety of deoxyribonucleases. In contrast, cell death in normal tis-
sues is mainly through apoptosis that releases DNA fragments
Value of circulating DNA concentration and integrity as a screening test for detection of cancer in an Egyptian cohort 195uniformly truncated (between 180 and 210 bp) produced by a
programed enzymatic cleavage process.16,17
CFDNA integrity is deﬁned as the presence of larger DNA
fragments in blood with different lengths or sizes >200 bp.37
Cancer and benign patients and control subjects showed bands
at 100 and 200 bp only, corresponding to the presence of short-
er DNA fragments, while 100% of cancer patients demon-
strated bands at 400 bp and approximately 78% of them
represented bands at 800 bp as well. Thus, longer DNA frag-
ments were present in all cancer patient samples, while they
were absent from benign and control subjects, i.e., the presence
of high-molecular-weight fragments was an indicator of cancer
and the absence of these longer fragments indicated the ab-
sence of malignant disease. These results were consistent with
many previous studies that revealed an increase of predomi-
nantly large DNA fragments in patients with breast,32 colon,33
lung,22 prostate,38 head and neck39 and renal cell carcinomas35
among many others.
DNA integrity index is deﬁned as the ratio of longer DNA
fragments (>200 bp) to shorter fragments (6200 bp).37 By
dividing the band intensities of larger fragments to shorter
ones (400 bp/100 bp), we obtained CFDNA integrity index.
This CFDNA integrity index was considered a better represen-
tative of the relative intensity of non-apoptotic cell death.
Where DNA clearance rate of the patients could directly con-
tribute to the absolute DNA level, but it would not signiﬁ-
cantly inﬂuence the values of CFDNA integrity index
because both the amounts of longer and shorter DNA frag-
ments would be similarly affected.42
Band intensity at 100 bp of all subgroups was relatively cor-
responding to the variation of CFDNA concentrations, while
band intensity at 200 bp was almost the same in all subgroups.
Therefore, the 100 bp band was relatively a better reﬂection of
the CFDNA concentration, and hence was used for calculating
the integrity index. We have chosen the larger fragments as
400 bp because it was present in 100% of cancer patients
and selected the shorter fragments as 100 bp as this band rela-
tively reﬂects the concentration of CFDNA.
Our results did not reveal any correlations between clinico-
pathological parameters (e.g. tumor size, stage, grade, metasta-
sis, etc.) and CFDNA concentration or integrity index. Except
for, the 800 pb band intensity which showed a strong positive
correlation with vascular invasion. That may be explained by
the fact that DNA released from malignant tumors into the
bloodstream was enhanced by vascular invasion. Since direct
lymphatic or blood ﬂow through the tumors enabled
dissemination of viable tumor cells and enhanced diffusion
of DNA released from necrotic or living tumor cells into the
bloodstream.40
Many other studies also reported that there was no correla-
tion of CFDNA integrity with any clinicopathological parame-
ters in various forms of cancer, in consistence with our
results.13,25,41–43 On the other hand, Umetani and his col-
leagues40 found that DNA integrity was positively correlated
to the size of invasive cancers and signiﬁcantly higher in the pres-
ence of lymphovascular invasion and lymph node metastasis.40
Notably, however, in HCC and colon subgroups, where
almost 40% of patients had low CFDNA concentrations result-
ing in lower mean CFDNA levels, yet, they had high CFDNA
integrity (800 bp band was present in all cases of these two
subgroups) and hence had higher integrity index compared to
other cancer subgroups. In other words, in colon and livercancers, alterations in DNA quality (fragmentation) rather
than quantity (concentrations) may better characterize tu-
mor-released DNA. Also, breast cancer that had the highest
CFDNA concentration of all solid tumors, it turned out to
have the lowest integrity index. These observations suggest that
there is no direct association between total CFDNA concentra-
tion and its integrity.
Screening for cancer in a large population, currently, needs
the combination of many techniques, including clinical, radio-
graphic, pathological and laboratory workup, which is both
money and time consuming. However, in the current study
we used one blood sample to identify cancer patients via plas-
ma DNA which was proven to be simple, sensitive, speciﬁc,
accurate, non-invasive, inexpensive and reproducible. So,
CFDNA test has all the properties of the ideal screening tumor
marker that can be used to identify cancer among subjects who
may be susceptible to have cancer.
To identify asymptomatic cancer patients in the large pop-
ulation it could be done in two steps. The ﬁrst step includes
extraction and quantiﬁcation of CFDNA. CFDNA being less
than 100 ng/ll might be indicative of no malignancy present
and a subject may be diagnosed as a cancer patient if CFDNA
P600 ng/ll. But if CFDNA is between 100 and 600 ng/ll, a
further conﬁrmation is needed. The second step is the detection
of the integrity of DNA fragments. The appearance of larger
fragments (400 bp) indicates the presence of cancer.
However, this test needs to be further validated on a larger
scale study before it can be applied to a large population, also
to further deﬁne the inclusion and exclusion criteria that en-
able the use of CFDNA as a screening test for malignancy.References
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